PI3K/AKT/mTOR通路
化学
药理学
生物利用度
体内
体外
蛋白激酶B
生物化学
信号转导
医学
生物
生物技术
作者
Yanan Yu,Yuqiao Han,Fupo Zhang,Zhenmei Gao,Tong Zhu,Suzhen Dong,Ming‐Liang Ma
标识
DOI:10.1021/acs.jmedchem.9b01736
摘要
PI3K-Akt-mTOR signaling pathway has been validated as an effective targeting pathway for cancer therapy. However, no PI3K/mTOR dual inhibitor has been approved by the FDA yet. Therefore, it is still essential to discover a candidate with good efficacy and low toxicity. In our design, a series of imidazo[1,2- a ]pyridine derivatives had been synthesized and subjected to activity assessment in vitro and in vivo . 15a was proved to be a potent PI3K/mTOR dual inhibitor with excellent kinase selectivity, modest plasma clearance, and acceptable oral bioavailability. Besides, 15a displayed significant inhibition of tumor growth in HCT116 and HT-29 xenografts without obvious effect on body weight.
科研通智能强力驱动
Strongly Powered by AbleSci AI